Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

UV-Visible Spectrophotometer

By Drug Discovery Trends Editor | August 25, 2010

evolutionThermo Fisher Scientific Inc. announced the launch of its Evolution 200 series of next-generation UV-Visible spectrophotometers featuring new INSIGHT software with CUE (Customized User Environment) scripting capabilities. The series includes three instruments which satisfy specific applications from standard quantitative analysis to research life science assays. Designed for routine QA/QC analyses in the life science, food and beverage and material science industries as well as offering fast data collection rates for kinetics measurements (up to 100 data points/sec), the instruments combine high performance and straightforward software, enabling personalized operation for greater productivity.

The Thermo Scientific Evolution 200 instruments feature high quality accessories and application specific technology to meet a wide range of sampling needs. Innovative Smart accessories enable accurate, cost-effective sample handling with automated software recognition and programmable control. Adding temperature control and fiber optic accessories can increase the instrument’s productivity and extend sampling options. In addition, the Evolution 220 and Evolution 260 Bio feature Application Focused Beam Geometry (AFBG) technology that tailors the instrument’s optical system to specific applications for microcells, solid sampling and fiber optics. The Evolution 260 Bio includes enhanced Thermo Scientific INSIGHT life science software designed specifically for the needs of life science laboratories, offering pre-programmed assay methods for increased accuracy and convenience.

Next-generation INSIGHT software has been designed to improve the user experience by simplifying method creation and results interpretation. The software’s data browser feature allows users to preview a thumbnail of results before opening the file and to sort by workbook type, file name and date for greater convenience. In addition, the workbook format helps organize data, method and accessory options by saving them all in one place.

The workbook can be reopened to continue capturing data using the same instrument configuration, with the aim to save time and improve the accuracy of results. INSIGHT software also includes CUE scripting capabilities, which enables the user to create a completely customized interface and simplified workflow. CUE works with INSIGHT to display only the most relevant information for the given application, to help improve accuracy, reproducibility and throughput in the laboratory.

The Evolution 200 series instruments are available in both local and computer controlled configurations. A locally controlled instrument with an embedded computer can be used to drive the new INSIGHT software package using touch screen technology. This easy-to-use ergonomic option allows users to perform all software functions using an embedded computer, increasing ease-of-use and saving valuable bench space while allowing sophisticated analysis and data reporting. Both local and computer controlled configurations can be run externally using the same INSIGHT software.

“We are very excited to be introducing our latest UV-Vis platform that simplifies the UV-Vis spectroscopy technique for users performing QA/QC analyses, but who still require high performance. The advanced interface as well as next generation INSIGHT software results in more straightforward and streamlined measurements of up to 100 data points per second from a single sample,” said Mike Jost, vice president and general manager of molecular spectroscopy and microanalysis for Thermo Fisher Scientific. “The Evolution 200 series was designed at our Center of Excellence for molecular spectroscopy in Madison, and further strengthens our portfolio of UV-Vis solutions ranging from entry-level through to high-end to best meet our customers’ needs.”

Thermo Fisher Scientific Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50